IBRX
NEUTRAL
$7.28
Live
ImmunityBio, Inc. · NASDAQ
Target $14.8
(+103.3%)
$1.83
52W Range
$12.43
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$7.52B
P/E
N/A
ROE
N/A
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ImmunityBio exhibits a severe divergence between fundamental financial health and growth trajectory. The deterministic baseline is critical, with a Piotroski F-Score of 1/9 indicating extreme financial weakness and a negative Price/Book ratio (-14.71) signaling that liabilities exceed assets. However, this is countered by explosive YoY revenue growth of 407% and a strong current ratio of 5.10, providing a necessary liquidity runway. While analysts maintain a 'strong_buy' rating based on future potential, the current valuation is speculative and disconnected from traditional value metrics.
Key Strengths
Hyper-growth revenue increase of 407% YoY
Strong short-term liquidity with a Current Ratio of 5.10
High Gross Margin of 99.33% indicating strong pricing power/product value
Positive analyst sentiment with a target price of $14.80
Recent positive momentum in EPS surprises over the last 4 quarters
Key Risks
Critical financial health as evidenced by a Piotroski F-Score of 1/9
Negative shareholder equity (Price/Book of -14.71)
Extreme valuation premium with a Price/Sales ratio of 66.36
Heavy operational losses with an operating margin of -168.95%
Bearish insider activity with consistent selling and zero buying
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
32
Weak
10
85
50
15
0
AI Verdict
Speculative Growth
Key drivers: Explosive Revenue Growth, Severe Balance Sheet Distress, High Liquidity Runway, Extreme Valuation Premium
Confidence
90%
Value
10/100
Trades at a massive premium to sales; traditional value metrics are non-applicable or negative.
Positives
No standout positives identified.
Watchpoints
- P/S ratio of 66.36 is unsustainable
- Negative Price/Book ratio
- No Graham Number available due to negative earnings/equity
Future
85/100
Growth rates are exceptional, driving the 'Strong Buy' analyst consensus.
Positives
- 407% YoY Revenue Growth
- Strong analyst price targets
- Improving EPS trend
Watchpoints
- High burn rate
Past
50/100
Recent performance is stellar, but long-term historical returns are negative.
Positives
- 1Y return of +195.9%
- 6M return of +208.5%
Watchpoints
- 5Y change of -54.8%
- History of missing earnings estimates in 2021-2023
Health
15/100
Deterministic health scores indicate a company in financial distress despite high cash liquidity.
Positives
- Current Ratio of 5.10
Watchpoints
- Piotroski F-Score of 1/9
- Negative Equity
- Operating Margin of -168.95%
Dividend
0/100
Typical for early-stage biotech focusing on growth over income.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$7.28
Analyst Target
$14.8
Upside/Downside
+103.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IBRX and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IBRX
ImmunityBio, Inc.
Primary
|
-54.8% | +372.7% | +195.9% | +208.5% | -12.0% | -0.3% |
|
BRKR
Bruker Corporation
Peer
|
-14.9% | -28.5% | -13.1% | +20.3% | +4.6% | +4.0% |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Peer
|
-23.4% | +107.3% | +265.3% | +85.2% | -10.6% | -8.0% |
|
MOH
Molina Healthcare, Inc.
Peer
|
-42.2% | -50.0% | -58.5% | -29.4% | -10.7% | -2.7% |
|
BIO
Bio-Rad Laboratories, Inc.
Peer
|
-49.6% | -35.1% | -15.9% | +12.3% | -1.7% | -5.4% |
IBR
ImmunityBio, Inc.
Primary
5Y
-54.8%
3Y
+372.7%
1Y
+195.9%
6M
+208.5%
1M
-12.0%
1W
-0.3%
BRK
Bruker Corporation
Peer
5Y
-14.9%
3Y
-28.5%
1Y
-13.1%
6M
+20.3%
1M
+4.6%
1W
+4.0%
ARW
Arrowhead Pharmaceuticals, Inc.
Peer
5Y
-23.4%
3Y
+107.3%
1Y
+265.3%
6M
+85.2%
1M
-10.6%
1W
-8.0%
MOH
Molina Healthcare, Inc.
Peer
5Y
-42.2%
3Y
-50.0%
1Y
-58.5%
6M
-29.4%
1M
-10.7%
1W
-2.7%
BIO
Bio-Rad Laboratories, Inc.
Peer
5Y
-49.6%
3Y
-35.1%
1Y
-15.9%
6M
+12.3%
1M
-1.7%
1W
-5.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-364.0
PEG Ratio
N/A
P/B Ratio
-14.71
P/S Ratio
66.36
EV/Revenue
71.39
EV/EBITDA
-33.61
Market Cap
$7.52B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-168.95%
Gross Margin
99.33%
ROE
N/A
ROA
-36.17%
Growth
Revenue and earnings growth rates
Revenue Growth
+407.0%
Earnings Growth
N/A
Q/Q Revenue Growth
+406.95%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
5.1
Strong
Quick Ratio
4.62
Excellent
Cash/Share
$0.24
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
99.0%
Op. Margin
-169.0%
Net Margin
-161.8%
Total Assets
$0.5B
Liabilities
$1.0B
Equity
$-0.5B
Debt/Equity
-2.00x
Operating CF
$-0.1B
CapEx
$-0.0B
Free Cash Flow
$-0.1B
FCF Yield
102%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-11
$N/A
2026-02-23
$-0.06
+37.9% surprise
2025-11-04
$-0.07
+30.0% surprise
2025-08-05
$-0.1
Healthcare Sector Comparison
Comparing IBRX against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
Revenue Growth
407.0%
This Stock
vs
88.16%
Sector Avg
+361.7%
(Fast Growth)
Current Ratio
5.1
This Stock
vs
3.58
Sector Avg
+42.5%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IBRX
ImmunityBio, Inc.
|
NEUTRAL | $7.52B | - | -% | -% | $7.28 | |
|
BRKR
Bruker Corporation
|
BEARISH | $7.65B | - | -1.1% | -0.6% | $50.33 | Compare |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
BULLISH | $7.71B | 34.41 | 75.5% | 18.5% | $55.05 | Compare |
|
MOH
Molina Healthcare, Inc.
|
NEUTRAL | $7.09B | 15.25 | 11.0% | 1.1% | $136.03 | Compare |
|
BIO
Bio-Rad Laboratories, Inc.
|
NEUTRAL | $8.0B | - | -9.5% | -26.4% | $296.57 | Compare |
IBRX
ImmunityBio, Inc.
NEUTRAL
Mkt Cap
$7.5B
P/E
-
ROE
-%
Price
$7.28
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-31 | SOON-SHIONG PATRICK | Officer, Director and Beneficial Owner | Option Exercise | 4,606,596 | $24,999,996 |
| 2026-02-24 | SIMON BARRY J. M.D. | Director | Sale | 75,000 | $900,788 |
| 2026-02-23 | SIMON BARRY J. M.D. | Director | Sale | 175,000 | $1,783,602 |
| 2026-02-23 | SELECKY CHRISTOBEL E. | Director | Sale | 25,000 | $250,000 |
| 2026-02-23 | SELECKY CHRISTOBEL E. | Director | Option Exercise | 25,000 | $74,500 |
| 2026-02-20 | SOON-SHIONG PATRICK | Officer, Director and Beneficial Owner | Stock Award | 114,329 | - |
| 2026-02-20 | SIMON BARRY J. M.D. | Director | Stock Award | 15,243 | - |
| 2026-02-20 | ADCOCK RICHARD | Chief Executive Officer | Stock Award | 152,439 | - |
| 2026-02-20 | SACHS DAVID C | Chief Financial Officer | Stock Award | 40,650 | - |
| 2026-02-20 | LAUER REGAN J | Officer | Stock Award | 4,065 | - |
| 2026-02-10 | SOON-SHIONG PATRICK | Officer, Director and Beneficial Owner | Stock Award | 274,122 | - |
| 2026-02-10 | ADCOCK RICHARD | Chief Executive Officer | Stock Award | 274,122 | - |
| 2026-02-10 | SACHS DAVID C | Chief Financial Officer | Stock Award | 82,236 | - |
| 2026-02-10 | LAUER REGAN J | Officer | Stock Award | 5,482 | - |
| 2026-01-20 | SIMON BARRY J. M.D. | Director | Sale | 151,967 | $989,364 |
SOON-SHIONG PATRICK
Officer, Director and Beneficial Owner
2026-03-31
4,606,596 shares
·
$24,999,996
SIMON BARRY J. M.D.
Director
2026-02-24
75,000 shares
·
$900,788
SIMON BARRY J. M.D.
Director
2026-02-23
175,000 shares
·
$1,783,602
SELECKY CHRISTOBEL E.
Director
2026-02-23
25,000 shares
·
$250,000
SELECKY CHRISTOBEL E.
Director
2026-02-23
25,000 shares
·
$74,500
SOON-SHIONG PATRICK
Officer, Director and Beneficial Owner
2026-02-20
114,329 shares
SIMON BARRY J. M.D.
Director
2026-02-20
15,243 shares
ADCOCK RICHARD
Chief Executive Officer
2026-02-20
152,439 shares
SACHS DAVID C
Chief Financial Officer
2026-02-20
40,650 shares
LAUER REGAN J
Officer
2026-02-20
4,065 shares
SOON-SHIONG PATRICK
Officer, Director and Beneficial Owner
2026-02-10
274,122 shares
ADCOCK RICHARD
Chief Executive Officer
2026-02-10
274,122 shares
SACHS DAVID C
Chief Financial Officer
2026-02-10
82,236 shares
LAUER REGAN J
Officer
2026-02-10
5,482 shares
SIMON BARRY J. M.D.
Director
2026-01-20
151,967 shares
·
$989,364
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
5 analysts
D. Boral Capital
2026-04-08
Buy
Buy
D. Boral Capital
2026-03-26
Buy
Buy
D. Boral Capital
2026-03-23
Buy
Buy
D. Boral Capital
2026-03-17
Buy
Buy
D. Boral Capital
2026-03-09
Buy
Buy
Piper Sandler
2026-03-04
Overweight
Overweight
D. Boral Capital
2026-02-23
Buy
Buy
HC Wainwright & Co.
2026-02-23
Buy
Buy
D. Boral Capital
2026-02-19
Buy
Buy
D. Boral Capital
2026-02-17
Buy
Buy
Past News Coverage
Recent headlines mentioning IBRX from our newsroom.
Newest → oldest
No matching news yet.